查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1562476

寡核苷酸合成市場規模、佔有率、成長分析、按產品、按應用、按最終用戶、按地區 - 產業預測，2024-2031

Oligonucleotide Synthesis Market Size, Share, Growth Analysis, By Product, By Application, By End User, By Region - Industry Forecast 2024-2031
出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

寡核苷酸合成的全球市場規模預計從2023 年的73 億美元成長到2022 年約60 億美元，預測期內（2024-2031 年）複合年成長率為17.4%，到2031 年將達到26.3 億美元。

由於研究、診斷、治療和藥物開發應用的不斷擴大，寡核苷酸合成市場正在經歷顯著成長。寡核苷酸是合成的短 DNA 或 RNA 分子，用於基因測試、研究和法醫學。基於寡核苷酸的療法，特別是反義寡核苷酸（ASO）、小干擾RNA（siRNA）和適體的發展，為治療各種遺傳性疾病、癌症和感染疾病。此外，個人化醫療的興起以及 CRISPR-Cas9 和其他基因編輯技術的出現正在推動對高品質寡核苷酸的需求。此外，寡核苷酸在 qPCR 和次世代定序(NGS) 等分子診斷中的不斷擴大應用進一步推動了市場成長。由於其先進的醫療基礎設施、大量的研發投資和強大的產業影響力，北美佔據了最大的市場佔有率。同時，由於醫療保健支出增加、生物技術產業擴張以及政府措施，預計亞太地區將經歷最快的成長。然而，治療性寡核苷酸的高成本、監管障礙以及對先進製造技術的需求等挑戰在一定程度上限制了市場的成長。

目錄

介紹

  • 研究目的
  • 定義
  • 市場範圍

調查方法

  • 資訊採購
  • 二手資料來源和主要資料來源
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 市場概況展望
  • 供需趨勢分析
  • 按細分市場的機會分析

市場動態及展望

  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務
  • 波特的分析

主要市場考察

  • 市場生態系統
  • 風險分析
  • 創新矩陣
  • 主要投資分析
  • 關鍵成功因素
  • 競爭程度

寡核苷酸合成市場：依產品

  • 市場概況
  • 基於寡核苷酸的藥物
    • 基於反義寡核苷酸的藥物
    • 基於 siRNA 寡核苷酸的藥物
    • 其他寡核苷酸藥物
  • 合成寡核苷酸
    • 底漆
    • 探測
    • DNA寡核苷酸
    • RNA寡核苷酸
    • 其他合成寡核苷酸
    • 自訂寡核苷酸
    • 預先設計的寡核苷酸
  • 試劑/耗材
  • 裝置

寡核苷酸合成市場：依應用分類

  • 市場概況
  • 治療用途
    • 疾病類型
    • 神經系統疾病
    • 罕見疾病
    • 其他疾病
  • 研究用途
    • PCR
    • 定序
    • 其他研究用途
  • 診斷用途

寡核苷酸合成市場：依最終用戶分類

  • 市場概況
  • 醫院
  • 製藥和生物技術公司
  • 診斷實驗室
  • 合約研究官（CRO）和首席行銷長（CMO）
  • 學術研究所

按地區分類的寡核苷酸合成市場規模

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東和非洲 (MEA)
    • 海灣合作理事會國家
    • 南非
    • 其他中東/非洲地區

競爭格局

  • 前5名企業對比
  • 主要企業市場定位（2023年）
  • 主要市場參與者所採取的策略
  • 近期市集活動
  • 主要企業市場佔有率（2023年）

主要企業簡介

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Eurofins Scientific
  • Agilent Technologies, Inc.
  • Kaneka Corporation
  • Azenta, Inc.
  • Sarepta Therapeutics, Inc.
  • AstraZeneca
  • Astellas Pharma Inc.
  • Jazz Pharmaceuticals PLC
  • Nippon Shinyaku, Co. Ltd.（NS Pharma, Inc.）
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • OligoMaker ApS（Part of TAG Copenhagen A/S）
  • Biolegio BV
  • Biolytic Lab Performance, Inc.
  • Bio-Synthesis, Inc.
  • Creative Biogene
  • Reprocell, Inc.
簡介目錄
Product Code: SQMIG35H2107

Global Oligonucleotide Synthesis Market size was valued at around 6 billion in 2022 and is expected to rise from USD 7.3 billion in 2023 to reach a value of USD 26.3 billion by 2031, at a CAGR of 17.4% over the forecast period (2024-2031).

The Oligonucleotide Synthesis Market has been growing significantly due to its expanding applications in research, diagnostics, therapeutics, and drug development. Oligonucleotides are short DNA or RNA molecules that are synthesized for use in genetic testing, research, and forensics. The development of oligonucleotide-based therapeutics, particularly antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, has opened new avenues for treating various genetic disorders, cancers, and infectious diseases. Additionally, the rise in personalized medicine and the emergence of CRISPR-Cas9 and other gene-editing technologies are propelling the demand for high-quality oligonucleotides. Moreover, the expanding application of oligonucleotides in molecular diagnostics, such as qPCR and next-generation sequencing (NGS), further fuels market growth. North America holds the largest market share due to advanced healthcare infrastructure, substantial R&D investments, and strong industry presence. Meanwhile, Asia-Pacific is expected to witness the fastest growth due to increasing healthcare expenditures, expanding biotechnology sector, and rising government initiatives to develop healthcare research infrastructure. However, challenges such as high costs of therapeutic oligonucleotides, regulatory hurdles, and the need for sophisticated technologies in manufacturing are restraining the market growth to some extent.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oligonucleotide Synthesis Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oligonucleotide Synthesis Market Segmental Analysis

Global Oligonucleotide Synthesis Market is segmented by Product, Application, End User, and region. Based on Product, the market is segmented into Oligonucleotide-based Drugs (Antisense Oligonucleotide-based drug, siRNA oligonucleotide-based drug, Other oligonucleotide-based drug), Synthesized Oligonucleotides (Primers, Probes, DNA Oligos, RNA Oligos, Other Synthesized Oligos (Customized Oligos, Predesigned Oligos), Reagents & Consumables, and Equipment. Based on Application, the market is segmented into Therapeutic Applications (Disease Type (Neurological Disorders, Rare Diseases, Other Diseases), Research Applications (PCR, Sequencing, Other Research Applications), and Diagnostic Applications. Based on End User, the market is segmented into Hospitals, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, CROs and CMOs, Academic Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Oligonucleotide Synthesis Market

One of the primary drivers of the oligonucleotide synthesis market is the rising adoption of oligonucleotide-based therapeutics, particularly in the treatment of rare genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics, such as ASOs and siRNAs, have gained significant attention due to their ability to target specific RNA molecules, allowing for highly targeted gene expression modulation. This specificity minimizes off-target effects and enhances the therapeutic index, making them highly desirable in personalized medicine. Additionally, advancements in delivery technologies, such as lipid nanoparticles and conjugation methods, have further enhanced the pharmacokinetic and pharmacodynamic properties of oligonucleotides, increasing their clinical efficacy. The FDA approval of drugs like Spinraza (nusinersen) for spinal muscular atrophy and Onpattro (patisiran) for polyneuropathy has further validated the therapeutic potential of oligonucleotides, encouraging biopharmaceutical companies to invest heavily in this promising field.

Restraints in the Global Oligonucleotide Synthesis Market

One of the significant restraints impacting the oligonucleotide synthesis market is the high cost associated with oligonucleotide therapeutics. The complexity involved in the chemical synthesis, purification, and scaling up of oligonucleotides leads to substantial production costs. These costs are often passed on to end users, resulting in expensive final products, which can limit accessibility, especially in developing regions with constrained healthcare budgets. Moreover, the development and production of oligonucleotide-based drugs require high levels of expertise, advanced technologies, and stringent regulatory approvals, which further increase the cost burden. The challenge is amplified by the need for specialized storage and delivery methods to maintain oligonucleotide stability and efficacy. These high costs pose a barrier for widespread adoption in clinical settings, slowing the overall market growth despite the potential benefits of oligonucleotide therapeutics.

Market Trends of the Global Oligonucleotide Synthesis Market

A significant trend shaping the oligonucleotide synthesis market is the rapid advancement in gene editing technologies, particularly CRISPR-Cas9 and related systems. These technologies have revolutionized genetic research by enabling precise, targeted alterations in DNA sequences, thereby enhancing the utility of oligonucleotides in gene modulation applications. Researchers are increasingly utilizing custom-synthesized oligonucleotides as guide RNAs (gRNAs) in CRISPR systems to target specific genes, paving the way for innovative therapeutic approaches to tackle previously untreatable genetic diseases. The integration of oligonucleotide synthesis with gene-editing technologies is not limited to therapeutic applications but also extends to functional genomics, agriculture, and synthetic biology. Companies are investing heavily in R&D to develop high-fidelity and efficient oligonucleotide synthesis platforms that cater to the growing demand for gene editing tools, thereby driving market growth and expanding the scope of genetic medicine.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Ecosystem of the Market
  • Risk Analysis
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Oligonucleotide Synthesis Market by Product

  • Market Overview
  • Oligonucleotide-based Drugs
    • Antisense Oligonucleotide-based drug
    • siRNA oligonucleotide-based drug
    • Other oligonucleotide-based drug
  • Synthesized Oligonucleotides
    • Primers
    • Probes
    • DNA Oligos
    • RNA Oligos
    • Other Synthesized Oligos
    • Customized Oligos
    • Predesigned Oligos
  • Reagents & Consumables
  • Equipment

Oligonucleotide Synthesis Market by Application

  • Market Overview
  • Therapeutic Applications
    • Disease Type
    • Neurological Disorders
    • Rare Diseases
    • Other Diseases
  • Research Applications
    • PCR
    • Sequencing
    • Other Research Applications
  • Diagnostic Applications

Oligonucleotide Synthesis Market by End User

  • Market Overview
  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • CROs and CMOs
  • Academic Research Institutes

Oligonucleotide Synthesis Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Danaher Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eurofins Scientific
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agilent Technologies, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kaneka Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Azenta, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sarepta Therapeutics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Jazz Pharmaceuticals PLC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nippon Shinyaku, Co. Ltd. (NS Pharma, Inc.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ionis Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • OligoMaker ApS (Part of TAG Copenhagen A/S)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biolegio BV
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biolytic Lab Performance, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Synthesis, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Creative Biogene
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Reprocell, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments